قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Israel's Technological Umbrella: "Irresponsible" demand for cancer treatment damages our reputation

Israel's Technological Umbrella: "Irresponsible" demand for cancer treatment damages our reputation



The Israeli high-tech and research industry organization, irresponsible and damaging, claims from a team of Israeli researchers that they have developed a concept that paves the way for cancer treatment.

The great amount of publicity that caused the obvious breakthrough, which, as Time Isaiah found, was not published for medical journalism, and that foreign experts say it is likely to be fake, causing damage to the Reputation of Israel in the field of life sciences, said the Israeli umbrella group.

"We welcome all the companies that are developing drilling technologies," said Karin Meyer Rubinstein, CEO of IATI. But, she warned, "The things the researchers have said have damaged the image of the Israeli industry for the life sciences." IATI is the organization that represents Israeli companies for high technology and life science, capital companies, multinational companies working in Israel, incubators and technology. transfer weapons to Israeli academics.

"This is a very irresponsible statement and we had many people around the world who wanted to clarify the topic," she said. "As we understand, there are critical stages of their research that still have to be fulfilled. These statements may harm the life science industry in Israel, which is globally positioned as one of the most serious and professional in the world. "

" The Israeli Life Sciences Industry consists mainly of very serious people with a wealth of experience. We expect them to behave more responsibly, especially before making such statements, "Meyer Rubinstein said. She noted that "it was asked by Israeli leaders in life sciences to clarify our position on this issue."

Requests for cancer treatment were made by researchers from the startup company Accelerated Evolution Biotechnologies Ltd. ) to Jerusalem Post earlier this week. The CEO of the company repeated the allegations in an interview with The Times of Israel on Wednesday but admitted that his research had not been published in reputable medical journals because, he says, the company could not afford that.

and Founder of the Launching Company "Accelerated Evolution Biotechnology" Ltd. (AEBI) Ilan Morad, with Hannan Ittaki, Chief Scientific Director, in their Laboratory (courtesy)

The Times of Israel reached many hospitals and experts in Israel to try to evaluate the allegations of a dramatic breakthrough, but they refused to comment, some noting that they had no direct information on the study. Other experts, beyond the ocean, however, sounded warnings about the researchers' claims, dismissing them as unreliable.

Dr. Ben Neil, director of the Perlmutter Cancer Center at New York University at Langgan Health, told New York Post that "cancer is a multitude of diseases, and it is very unlikely that this company has found a cure for cancer more than a cure for He said that "this is more likely to be one of the long lines of false, irresponsible and ultimately brutal false promises for cancer patients."

Ilan Morad, CEO and founder of AEBi, told Times Israel on Thursday that the reaction of critics who have not seen the company's results is "criticizing a book without reading it."

He repeated that the company could start treating patients in clinical trials hoping to start "pretty quickly". "And say," We're not saying the drug will will be approved for one year, our technology is innovative and we have filed a patent application on it, and this application is at an advanced stage and until now patent attorneys have considered our technology to be innovative.

"We're working on curing cancer," Morad said in an interview with Times Island, published on Wednesday. , repeating the allegations made by the company to Jerusalem Post earlier this week. "We still have a long way to go, but in the end we believe we will have a cure for all types of cancer patients and very few side effects," he said. has not published his research in medical journals as normal because "can not afford", but the results of preclinical studies are "very good".

a small company, "he said. "The publication of an article requires a lot of effort and a lot of money and we can not afford it." He added: "If we were a big company with a lot of money, that would be the first thing we would do. If I have $ 100,000, what are they spending? he asked. "Progress in research and finding more and more focused on peptides, or performing many experiments to write an article? What would you do if you had to choose? "

In the conventional development process, medical researchers who make a discovery collect their material and present a document for legitimate medical journals in the hope that editorial committees of journals will confirm their findings and publish the discovery. The higher the prestige of the publication, the greater the obvious value of the discovery. Researchers do not have to pay for legitimate medical journals to publish their findings.


Source link